Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis reportPriya S. Kishnani, Yin‐Hsiu Chien, Si Houn Hahn et al.|Genetics in Medicine|2022Cited by 53
Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective studySi Houn Hahn, Priya S. Kishnani, David Kronn et al.|Genetics in Medicine|2018Cited by 31
Motor Responses in Pediatric Pompe Disease in the ADVANCE Participant CohortPriya S. Kishnani, Kristina An Haack, Meredith C. Foster et al.|Journal of Neuromuscular Diseases|2022Cited by 5
Acute Severe Behavioral Disturbance Requiring Parenteral Sedation in Pediatric Mental Health Presentations to Emergency Medical Services: A Retrospective Chart ReviewElyssia Bourke, Franz E Babl, Ned Douglas et al.|Annals of Emergency Medicine|2023Cited by 5
The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase AlfaDavid Kronn, James Davison, Alexander Broomfield et al.|The Journal of Pediatrics|2025Cited by 3